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Introduction and objectives. To irradiate the whole pelvis in high-risk prostate cancer is a subject of debate, however it may improve
biochemical disease-free survival in selected patients with high risk of positive pelvic lymph nodes. The spatial relationship
within the pelvis among the lymph nodes, small and large bowel, bladder and rest of the tissues limits the dose escalation that
can be safely delivered. We assessed the toxicity of pelvic VMAT with hypofractionated simultaneous integrated boost (SIB) to
the prostate for patient with high-risk prostate cancer.
Material and methods. A retrospective toxicity analysis was performed in 10 consecutive patients treated deﬁnitively with pelvic
SIB-VMAT, all of whom also received androgen suppression. The VMAT plans were designed to deliver 67.5Gy (2.5Gy/fr) to the
prostate, while simultaneously delivering 59.4Gy (2.2Gy/fr) to the seminal vesicles, and 48.6Gy (1.8Gy/fr) to the pelvis nodes in
27 fractions. Prostate dose was equivalent to 78Gy at 2Gy per fraction considering an alpha/beta of 1.5Gy. VMAT was delivered
by two arcs. Dose constraints for bladder and rectal volumes receiving 70, 60 and 40Gy were les than 25, 40 and 60% respectively.
To score the toxicity we used The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
Results. One patient showed a biochemical relapse during the follow-up period. The most common acute Grade 2 events were
cystitis (80%) and urinary frequency/urgency (90%). Rectal acute toxicity Grade 2 with mucosal discharge was present in 70% of
patients. At a median follow-up of 6 months, no late toxicity exceeding Grade 2 was seen. Mean bowel volume for V30, V40, V50
and V60 were 54.39, 32.48, 4.06, 0.36 cc respectively. Grade 2 acute or late bowel toxicity was not associated with bowel volume
receiving V30, V40, V50 and V60. Acute or late bladder and rectal toxicity did not correlate with any of the dosimetric parameters
examined.
Conclusion. Pelvic VMAT with SIB to the prostate was well tolerated in this series, with acceptable rate of toxicity. SIB-VMAT
combines pelvic radiotherapy and hypofractionation to the primary site and offers an accelerated approach to treating high-risk
disease. Additional follow-up is necessary to fully deﬁne the long-term toxicity after hypofractionation whole pelvic treatment
combined with androgen suppression.
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Ductal adenocarcinoma of the prostate (DAP) is considered a rare variant in contrast with the more common acinar adenocar-
cinoma (AAP), it represents only 0.4–0.8% of all prostate cancer, and the mixed histology no more than the 5%. We report here
a case of DAP in a 68-year old man who has been followed-up since 2001 because of PSA increase (6.4ng/ml) with negative
biopsy for prostate cancer at that moment. In 2011 with new rise of PSA, to 19.6ng/ml the biopsy result came as adenocarcinoma
of large ducts. The patient underwent radical-prostatectomy with the ﬁnal result of inﬁltrating ductal adenocarcinoma of the
prostate with an in situ intraductal component, that contacts with superior surgical margin next to seminal vesicle. Despite the
successful surgery, the PSA 9 months after surgery, was 0.4ng/ml, persistent disease was assumed and had been treated with
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